Veritas Institute Friday, July 30, 2010
  
Intended Audience
This symposium will primarily target hematologists, hematologist/oncologists, and medical
oncologists who need to be kept apprised of the rapidly changing developments in this
therapeutic area.  

Learning Objectives
  • You will be better able to review the molecular mechanisms involved in CML pathophysiology and imatinib resistance, and evaluate the utility of frequent molecular and cytogenetic testing in patients with CML who are receiving TKIs in order to improve patient outcomes.
  • In order to develop optimal and better personalized treatment regimens utilizing present and future therapeutic options in patients with CML, you will be able to critically examine recent clinical trials and data analyses and consider the role of mutation analysis in influencing treatment decisions.
  • You will be better able to consider adverse event profiles associated with immediate and prolonged use of TKIs to optimize therapeutic decisions for your patients with CML.
 
Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 
Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 3.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.  

To Receive CME Credit
  • Participate in the symposium
  • Complete the CME Activity Evaluation and Request for Credit Form
  • Hand in the form at the conclusion of the meeting to receive your certificate of credit
  • Alternatively, you may fax or mail the evaluation form to Veritas Institute for Medical Education, Inc. at the number or address listed. You will receive your certificate of credit within 2 weeks.
Financial and Unlabeled Use Disclosures
The relevant financial relationships of those persons in a position to control the content of
this CME activity will be disclosed prior to the start of the educational activity. Participants
are advised that this CME activity will contain references to unlabeled/unapproved/investigational uses of drugs to treat patients with CML.
 
Disclaimer
The opinions expressed in this activity are those of the presenters and do not necessarily
reflect those of Veritas Institute for Medical Education, Inc. or Bristol-Myers Squibb
Company. Please consult the appropriate package insert for full prescribing information
on all drug therapies discussed.
 
THERE IS NO FEE FOR THIS ACTIVITY